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In this randomised double-blind study, patients 40 years old with COPD, a smoking history of
10 pack-years, a pre-bronchodilator FEV1 of60% predicted and an FEV1/FVC of70% received
tiotropium 5 mg or placebo via Respimat inhaler once daily for 48 weeks. Other medications
were permitted except inhaled anticholinergics. Co-primary endpoints were trough FEV1 and
the time to first exacerbation. Adverse events were followed and vital status regularly assessed.
In all, 3991 patients (mean age, 65 years [SD, 9 years]) were evaluable. Mean baseline FEV1was
1.11 L (0.40 L) or 40% (12%) of predicted normal. Adjusted mean differences in trough FEV1 and
trough FVC atWeek 48 (tiotropiumminus placebo) were 102 and 168ml respectively (p< 0.0001,
both). Tiotropium delayed time to first exacerbation relative to placebo (hazard ratio [HR], 0.69
[95% CI, 0.63e0.77]) and time to first hospital-treated exacerbation (HR, 0.73 [0.59e0.90]).
SGRQ score at Week 48 was 2.9 units lower with tiotropium (p < 0.0001). Adverse and serious
adverse events were balanced across treatment groups and similar in profile to previous tiotro-
pium trials. The rate ratio for a major adverse cardiovascular event during the treatment peri-
od þ 30 days was 1.12 (0.67e1.86). By the end of planned treatment (Day 337) 52 patients on
tiotropium (incidence rate per 100 years, 2.94) and 38 on placebo (2.13) had died (HRZ 1.38
[0.91e2.10]; pZ 0.13).
Lung function, exacerbations and quality of life were improved by tiotropium 5 mg Respimat
but a numerical imbalance was seen in all-cause mortality.
The protocol is registered on the European Clinical Trials Database as trial number 2006-1 406 6901; fax: þ27 21 406 6902.
.ac.za (E.D. Bateman).
0 Elsevier Ltd. All rights reserved.
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ª 2010 Elsevier Ltd. All rights reserved.Introduction
The clinical value of the long-acting anticholinergic tio-
tropium (Spiriva; Boehringer Ingelheim, Ingelheim,
Germany) in the maintenance treatment of chronic
obstructive pulmonary disease (COPD) was initially
demonstrated in a series of studies with a dry powder
inhaler presentation of the drug (Spiriva HandiHaler).
These trials showed that tiotropium improves lung function,
dyspnoea, exercise duration and health-related quality of
life (HRQoL), as well as reducing hyperinflation and the risk
of exacerbations and associated hospitalisations.1e6 More
recently, an alternative aqueous aerosol presentation of
tiotropium has been developed, which is delivered via the
Respimat Soft Mist Inhaler, a multidose propellant-free
device. The properties of the aerosol produced by this
inhaler, in particular its high fine particle fraction and its
low speed compared with aerosols from a pressurised
metered-dose inhaler (pMDI),7,8 result in more drug being
deposited in the lung and less in the mouth and throat.9,10
In two largemulticentre trials of identical design in which
tiotropium 5 and 10 mg in the Respimat inhaler were given
to COPD patients once daily for 48weeks, significant benefits
over placebo were shown for the four co-primary endpoints,
i.e. the trough response for forced expiratory volume in 1 s
(FEV1), HRQoL, dyspnoea and the rate of exacerbations.
11
Apart from a higher incidence of typical anticholinergic
side-effects such as drymouth and constipation, the adverse
event profile was similar to that of placebo.11 These results
have subsequently supported the approval in 55 countries to
date of 5 mg once daily in the Respimat inhaler as the
standard dose for use in COPD patients.
The objective of the current study was to assess clinical
efficacy and safety of one-year’s treatment with tiotropium
5 mg delivered via Respimat in COPD patients, particularly
its effect on exacerbations. However, to reflect more
closely the typical positioning of tiotropium in COPD
management, patients were permitted to use a wider range
of concurrent COPD medications during the study, including
long-acting b2-agonists (LABAs) and inhaled corticosteroids
(ICS); the only disallowed medications were inhaled anti-
cholinergics. The two co-primary endpoints were trough
FEV1 (at 48 weeks) and time to first exacerbation. Safety
and tolerability were assessed during the on-treatment
period plus 30 days, and vital status was ascertained for all
patients (whether or not they had completed study treat-
ment) until 30 days after the end of the planned 48 week
treatment period.
Methods
Study design and compliance
This clinical trial (Boehringer Ingelheim study number
205.372) used a randomised, double-blind, parallel-group
design, and was conducted in 336 outpatient centresspanning five continents and involving 31 countries. The
trial was carried out in compliance with principles laid
down in the Declaration of Helsinki and in accordance
with the International Conference on Harmonisation
(ICH) Harmonised Tripartite Guideline for GCP. The
protocol and all amendments were approved by institu-
tional review boards at each centre, and all participants
gave written informed consent. The protocol is registered
on the European Clinical Trials Database as trial number
2006-001009-27 and in the ClinicalTrials.gov database as
NCT00387088.
Patients
COPD patients of either sex were eligible for study entry if
they were aged 40 years, had pre-bronchodilator FEV1 of
60% of predicted normal12 and a ratio of FEV1 to forced
vital capacity (FVC) of 70%, and were current or ex-
smokers (smoking history of 10 pack-years). Patients
were excluded if they had a significant disease other than
COPD that, in the investigator’s judgment, could affect the
patient’s ability to complete the trial, or if they had clin-
ically significant abnormal results of haematology, urinal-
ysis, or blood chemistry tests, a history of asthma or
allergic rhinitis, or a blood eosinophil count of 600/mm3.
Other exclusion criteria included previous lung resection
surgery, participation in a pulmonary rehabilitation pro-
gramme in the previous 6 weeks, and regular daytime
oxygen use (>1 h/day). Less stringent exclusion criteria
relating to cardiovascular disorders were employed, with
the aim of making the patient sample more representative
of the range of COPD patients typically encountered in
clinical practice, but patients with a history of unstable
arrhythmias, myocardial infarction (MI) in the previous 6
months or heart failure requiring in-hospital treatment in
the previous 12 months were excluded. Patients who had
previously used tiotropium delivered via Respimat were
also excluded, but those who had previously used tio-
tropium delivered via HandiHaler could enter the trial if
they stopped taking it at least 28 days before the ran-
domisation visit.
Treatments
All patients attended a screening visit at which they were
given training in the use of the Respimat inhaler. Seven
days later, patients meeting the entry criteria were
randomly assigned in a 1:1 ratio to 48 weeks’ treatment
with either tiotropium 5 mg (two puffs of 2.5 mg each) or
placebo (two puffs) both inhaled via the Respimat inhaler
once daily in the morning; identity of treatments was
blinded to investigators, assessors and patients. Treatment
allocation was determined by a computer-generated ran-
domisation code provided by Boehringer Ingelheim. Ran-
domisation was stratified by study centre and within
centres, and performed in blocks to ensure balanced
distribution of the treatment groups at any time.
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the trial had no access to the allocation sequence until
after the trial was completed.
Salbutamol pMDI was provided to all patients for use as
rescue medication at any time during the study. All respi-
ratory medications were permitted during the trial other
than inhaled anticholinergics.
Efficacy endpoints
The study had two co-primary efficacy endpoints: trough
FEV1 response, i.e. the difference between pre-dose FEV1
on Day 1 of the treatment period and the corresponding
value after 48 weeks of treatment, and time to first COPD
exacerbation. Exacerbations were defined as a complex of
respiratory events or symptoms that lasted 3 days and
required treatment with antibiotics and/or systemic
corticosteroids, or prompted the investigator to change the
patient’s regular respiratory medication. Secondary effi-
cacy endpoints included trough FEV1 response after 4 and
24 weeks and trough FVC response at 4, 24 and 48 weeks,
the number of exacerbations per patient, the number of
patients with at least one exacerbation (exacerbations
requiring hospitalisation were counted separately), and
the time to the first exacerbation that required hospital-
isation. HRQoL (change from baseline in total and domain
scores of the St. George’s Respiratory Questionnaire
[SGRQ] after 24 and 48 weeks) was also a secondary effi-
cacy endpoint.
At the screening and baseline visits, and the visits at the
end of weeks 4, 24 and 48, the administration of concom-
itant medications before pulmonary function tests (PFTs)
was restricted to avoid interference with the tests. The
restricted period was 8 h for short-acting b2-agonists
(SABAs), 12 h for any LABA- or ICS-containing medication,
and 24e48 h for xanthines, depending on the drug release
kinetics of the formulation.
Safety
Adverse events were collected at all clinic visits. Electro-
cardiography (ECG) was performed at screening, after 4
weeks, and at the end of patient participation in the trial.
Mortality was assessed for the planned duration of the trial
for all patients, including those who prematurely dis-
continued study medication.
Statistical analysis
Changes in trough FEV1 and FVC were analysed using an
analysis of covariance (ANCOVA) with terms for study
centre, LABA use (LABA treatment that started no later
than the day of randomisation and that continued for at
least one more day) and treatment as fixed effects, and
baseline FEV1 and baseline FVC as covariates, respectively.
Time to first exacerbation was analysed with the Cox
proportional hazards model including terms for centre,
treatment and LABA use. The two co-primary endpoints
were tested sequentially, to preserve the Type I error rate
at 0.05. The co-primary endpoints were analysed in all
patients who were randomly assigned and treated and whoprovided a trough FEV1 measurement at baseline and at
least one subsequent visit.
Analysis of other exacerbation endpoints was done using
the following tests: the log rank test (life-table method) for
time to first exacerbation, the WilcoxoneManneWhitney
test (both naı¨ve and exposure-adjusted) and generalised
linear regression modelling (assuming both a Poisson and
negative binomial distribution) for the number of exacer-
bations per patient, and logistic regression for the propor-
tion of patients experiencing at least one exacerbation.
SGRQ scores were analysed by ANCOVA.
Assuming a standard deviation in trough FEV1 of 0.229 L,
1500 completed patients per treatment group would enable
detection of a difference between study treatments of
0.13 L in mean trough FEV1 response, with a significance
level of 5% (two-sided) and at least 99% statistical power.
This number of patients would also enable detection of
a proportional hazard of 0.85 (tiotropium relative to
placebo) for the time to first exacerbation in a log rank
test, with a significance level of 5% (two-sided) and 80%
statistical power, assuming that the proportion of patients
experiencing 1 exacerbation was 37.2 and 42.1% for tio-
tropium and placebo respectively.
For fatal events, Cox regression analysis (using treat-
ment as a covariate) was used to estimate the hazard ratio
and 95% confidence interval (CI) for time to death, which
was defined as the time from first dose of study treatment
to the date of death. For the primary analysis of time to
death (for the planned treatment period), patients were
censored at the earlier of Day 337 or the last day they were
known to be alive. The probability of survival was also
analysed using KaplaneMeier analysis and the log rank test.
Incidence rates were calculated for all events by dividing
the number of patients reporting an event by the patient-
years at risk, expressed per 100 patient-years at risk. Fatal
events, cause of death, and relationship between study
treatment and fatal events were reviewed by an indepen-
dent committee consisting of two chest physicians,
a cardiologist and a statistician. For adverse events, 95% CIs
for hazard or rate ratios that excluded the value of 1
indicate a nominal p value of <0.05.
Results
Study population
Of 5483 patients screened, 3991 were randomly allocated
study treatment (Fig. 1). Seventy-four patients at one
centre were excluded from safety and efficacy analyses
because of uncertainty about assignment and administra-
tion of study treatment, and a further 25 patients at two
other centres were excluded from efficacy analyses
because of serious non-compliance or questionable data.
The treated set (for safety analyses) therefore comprised
3917 patients and the full analysis set (for efficacy anal-
yses) comprised 3892 patients. Recruitment started in
October 2006 and finished in December 2007.
At the screening visit, demographic and clinical char-
acteristics of patients in the treated set (including lung
function measurements) were well matched between
treatment groups (Table 1). The mean age of all patients
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Figure 1 Patient flow through study.
Tiotropium Respimat in COPD patients 1463was 64.8 years (SD, 9.0 years) and there were more ex-
smokers (64.2%) than current smokers (35.8%). There were
slightly more men in the tiotropium group (78.1 vs. 77.0%).
At the randomisation (baseline) visit, mean FEV1 was
1.11 L, equating to 40.3% of predicted normal (Table 1).
Concurrent use of other COPD medications was similar in
the two treatment groups. The most common medications
were LABAs and ICS, each used by just over half the
patients (Table 1).
The protocol required that the dosage of concomitant
pulmonary medications remain stable as far as possible
throughout the randomised treatment period, and that
dosage changes and any new medications added during the
study be documented. The 2091 patients who were taking
LABAs at randomisation continued to take them for 98.9%
(tiotropium) and 99.0% (placebo) of the randomised treat-
ment period, whereas 1826 patients who were not taking
a LABA at randomisation took them for 2.1% and 3.3% of the
period, respectively. One hundred patients started LABAs
after randomisation (tiotropium, 35; placebo 65).
More patients in the placebo group discontinued (373;
18.6%) than in the tiotropium group (318; 16.0%), the most
common reason being adverse events (Fig. 1); in patients
with very severe COPD (Global Initiative for ChronicObstructive Lung Disease [GOLD] stage IV) at baseline, 92 of
291 (31.6%) on placebo and 56 of 207 (18.2%) on tiotropium
discontinued study treatment. Mean baseline FEV1 in all
patients who discontinued (1.07 L [SD, 0.38 L] for tio-
tropium and 0.99 L [SD, 0.40 L] for placebo) was lower than
in those who completed the study (1.12 L [0.40 L] and
1.13 L [0.39 L], respectively). Vital status was known for
99% of randomly allocated patients at the end of Day 337
(end of treatment period) and for 60% at Day 367 (30 days
after treatment completion).
Efficacy
Co-primary endpoints
After 48 weeks of the study, the adjusted mean increase
from baseline trough FEV1 was significantly greater in the
tiotropium group (119 ml) than the placebo group (18 ml).
The adjusted mean difference between treatments was
102 ml (95% CI, 85e118 ml; p < 0.0001) (Table 2).
The time to first exacerbation was delayed by treatment
with tiotropium. During the treatment period, 685 (35.3%)
patients in the tiotropium group and 842 (43.1%) in the
placebo group had at least one exacerbation, representing
a significant risk reduction with tiotropium (hazard ratio
Table 1 Characteristics of all COPD patients at the screening and randomisation visits (treated set). Except for distribution
data, all values are means (with standard deviation in parentheses).
Tiotropium 5 mg
Respimat (n Z 1952)
Placebo
(n Z 1965)
Screening visit
Men:women (%) 78.1:21.9 77.0:23.0
Age (years) 64.8 (9.1) 64.8 (9.0)
Current smoker:ex-smoker (%) 35.7:64.2 35.9:64.1
Smoking history (pack-years) 46.0 (26.1) 45.0 (26.5)
Time since COPD diagnosis (yrs) 8.34 (7.00) 8.11 (6.52)
Pre-bronchodilator FEV1 (L) 1.097 (0.392) 1.088 (0.395)
Pre-bronchodilator FEV1 (% predicted normal) 39.86 (12.03) 39.83 (11.95)
Pre-bronchodilator FVC (L) 2.350 (0.737) 2.358 (0.769)
Pre-bronchodilator FEV1/FVC (%) 47.20 (10.81) 46.74 (10.69)
Post-bronchodilator FEV1 (L)
a 1.244 (0.442) 1.240 (0.449)
Post-bronchodilator FEV1 (% predicted normal)
a 45.21 (13.54) 45.36 (13.64)
Reversibility of FEV1 (%) 14.79 (16.69) 15.14 (17.01)
Post-bronchodilator FVC (L)a 2.595 (0.789) 2.619 (0.836)
Post-bronchodilator FEV1/FVC (%)
a 48.45 (11.26) 47.92 (11.26)
Randomisation visit (baseline)
FEV1 (L) 1.109 (0.394) 1.101 (0.397)
FEV1 (% predicted normal) 40.29 (12.02) 40.34 (12.11)
FVC (L) 2.379 (0.728) 2.384 (0.760)
Proportion taking pulmonary medications (%)b
Any medication 79.4 78.3
Long-acting b2-agonists 54.2 52.6
Short-acting b2-agonists 36.7 37.2
Inhaled corticosteroids 56.0 56.1
Oral corticosteroids 2.4 2.8
Xanthines 23.4 23.0
Mucolytics 9.6 9.1
Short-acting anticholinergics 1.6 1.9
Supplementary oxygen 1.7 1.6
COPD Z chronic obstructive pulmonary disease; FEV1 Z forced expiratory volume in 1 s; FVC Z forced vital capacity.
a Post-bronchodilator values measured 30 min after salbutamol 4  100 mg.
b Medications taken before or on the randomisation day and for 1 day thereafter; only those taken by >1.5% of all patients are shown.
1464 E.D. Bateman et al.[HR]Z 0.69 [95% CI, 0.63e0.77]; p < 0.0001). A significant
difference was also found in a sensitivity analysis, in which
time to first exacerbation was calculated using life-table
analysis (Table 4). KaplaneMeier analysis of time to first
exacerbation is shown in Fig. 2a.
Secondary efficacy measures
Trough FEV1 values at weeks 4 and 24 were significantly
higher in the tiotropium group than in the placebo group,
differences being 93 and 103 ml respectively (p < 0.0001;
Table 2). In addition, trough FVCwas significantly higherwith
tiotropium than with placebo at weeks 4, 24 and 48, the
differences ranging between 151 and 168 ml (p < 0.0001;
Table 2).
The rate of exacerbations per patient-year was signifi-
cantly lower with tiotropium during the treatment period
than with placebo (0.69 and 0.87 respectively), as was the
rate of exacerbations requiring hospitalisation (0.12 and
0.15 respectively) (Table 3).
The time to the first exacerbation requiring hospital
treatment was also delayed by treatment with tiotropium(Table 3). At least one such exacerbation was recorded
for 161 (8.3%) patients in the tiotropium group and 198
(10.1%) in the placebo group during the treatment period,
representing a significantly lower risk with tiotropium
(HR Z 0.73 [95% CI, 0.59e0.90]; p < 0.005) and
a statistically significant difference between treatments
was also found in the life-table analysis. The
KaplaneMeier analysis of this endpoint is shown in
Fig. 2b.
Mean total SGRQ scores fell from baseline in both
groups, showing improvement in HRQoL, but the change
was significantly greater with tiotropium than placebo. At
week 24, the adjusted mean difference in total scores
between tiotropium and placebo was 2.2 and at week
48, it was 2.9 units (p < 0.0001 at both time points).
Although both these differences were smaller than the
minimum clinically important difference for the SGRQ of
4 units,13 the proportion of responders (those whose total
score fell by 4 units from baseline) was significantly
higher in the tiotropium group than the placebo group
(Table 4).
Table 2 Changes from baseline in morning (pre-dose) trough spirometry measures by treatment group. Data shown are
adjusted means with standard error of the mean in parentheses unless otherwise stated.
Tiotropium 5 mg
Respimat
(n Z 1889)
Placebo
(n Z 1870)
Adjusted mean
difference
(95% CI)
P value
Co-primary endpoint
FEV1 (ml), Week 48 119 (7) 18 (7) 102 (85e118) p < 0.0001
Secondary endpoints
FEV1 (ml), Week 4
a 110 (5) 17 (5) 93 (80e106) p < 0.0001
FEV1 (ml), Week 24 121 (6) 18 (6) 103 (88e118) p < 0.0001
FVC (ml), Week 4a 176 (9) 25 (9) 151 (127e174) p < 0.0001
FVC (ml), Week 24 179 (10) 19 (10) 160 (135e186) p < 0.0001
FVC (ml), Week 48 168 (11) 1 (11) 168 (141e196) p < 0.0001
CI Z confidence interval; FEV1 Z forced expiratory volume in 1 s; FVC Z forced vital capacity.
a Number of patients for Week 4 data: tiotropium, 1879; placebo, 1866.
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When the study population was split into two subgroups
according to whether or not patients were taking LABAs at
randomisation, the tiotropium and placebo groups were still
well matched for demographic and clinical characteristics
and previous COPD medication in both subgroups (Table 5).
In the LABA users, the tiotropium group had slightly more
men (77.8 vs. 74.2%) than placebo; the opposite was true
(78.4 vs. 80.2%) for the LABA non-users. Comparison of LABA
users with LABA non-users showed minimal differences in
pre-bronchodilator lung function, although post-bronchodi-
lator values showed the LABA users to have slightly more
severe disease and slightly less reversibility of FEV1 to sal-
butamol than the LABA non-users. In line with this, thereTable 3 Exacerbation measures by treatment group, including
by life-table analysis).
Tiotropium 5 mg
Respimat
Co-primary endpoint
Time to first exacerbation
Patients having 1 exacerbation
during treatment
685 (35.3%)
Sensitivity analysis of time to
exacerbation (days, lower
quartile & 95% CI)
169 (153e200)
Secondary endpoints
Mean number of exacerbations per patient per year (& 95% CI)
Any exacerbation 0.69 (0.64e0.74)
Exacerbations requiring
hospitalisation
0.12 (0.11e0.14)
Time to first exacerbation requiring hospitalisation
Patients having 1 exacerbation
during treatment
161 (8.3%)
Sensitivity analysis of time
to exacerbation
NE
CI Z confidence interval; NE Z lower quartiles for time to event notwere more GOLD stage III and IV patients among LABA users
(64.5%) than LABA non-users (56.9%), and pre-study use
of most COPD medications, notably ICS, was higher in the
LABA users.
For change from baseline in trough FEV1 at week 48,
LABA use had no effect on the degree of superiority of
tiotropium over placebo, but the absolute changes from
baseline were larger (for tiotropium and placebo) in LABA
non-users than LABA users (Table 6). A very similar pattern
of results was seen for SGRQ scores: LABA non-users had
greater gains in HRQoL than LABA users, particularly at
week 48, and the proportion of responders at week 48 was
slightly higher in LABA non-users (Table 6). For other lung
function measures, there was no interaction between LABAresults of sensitivity analysis (time to exacerbation measured
Placebo Hazard ratio (HR) or
relative rate (RR);
95% CI; p value
842 (43.1%) HR Z 0.693 (0.625e0.769);
p < 0.0001
119 (108e134) p < 0.0001
0.87 (0.82e0.93) RR Z 0.79 (0.72e0.87);
p < 0.0001
0.15 (0.14e0.17) RR Z 0.81 (0.70e0.93);
p < 0.005
198 (10.1%) HR Z 0.728 (0.589e0.901);
p < 0.005
NE 0.0191
estimable.
Table 4 Change in health-related quality of life (St George’s Respiratory Questionnaire [SGRQ] scores) by treatment group.
Tiotropium 5 mg
Respimat
Placebo Difference, mean and
95% CLs
Change from baseline in total score (units)
Week 24 4.8 2.6 2.2 (3.1, 1.3); p < 0.0001
Week 48 4.7 1.8 2.9 (3.9, 2.0); p < 0.0001
Number (%) of respondersa
Week 24 860 (50.9%) 701 (42.0%) 8.9% (5.5, 12.2%); p < 0.0001
Week 48 836 (49.5%) 690 (41.4%) 8.1% (4.7, 11.5%); p < 0.0001
CL Z confidence limit.
a Patients with a reduction in SGRQ score from baseline of 4 units.
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tiotropium and placebo. Tiotropium was significantly
superior to placebo in LABA users and non-users in respect
of the co-primary exacerbation endpoint (Table 6),
although fewer LABA non-users (28.0% tiotropium; 38.5%
placebo) had at least one exacerbation during the treat-
ment period than LABA users (41.5 and 47.3%, respec-
tively). For the time to first exacerbation requiring
hospitalisation, the reduction in risk with tiotropium was
significant in LABA users (HR Z 0.70; 95% CI, 0.53e0.93;
p Z 0.014), but not in LABA non-users (HR Z 0.84; 95% CI,
0.59e1.20; p Z 0.341).No of patients
Tiotropium
Placebo
Hazard ratio = 0.693
(95% CI, 0.625, 0.769)
p =  <.0001 (log-rank test)
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Figure 2 KaplaneMeier analysis of the probability of a COPD
exacerbation during the on-treatment period: a) for all exac-
erbations; b) for exacerbations requiring hospitalisation.Safety
The proportion of adverse events and serious adverse
events reported by patients in the two treatment groups
during the on-treatment period (up to the last dose
taken þ 30 days follow-up) was similar (Table 7). When
adverse events were grouped by organ class, incidence
rates per 100 patient-years (IRs) for the two treatments
were mostly similar, with differences being statistically
significant for three: lower respiratory system disorders (IRs
of 70.5 and 87.0 for tiotropium and placebo respectively,
rate ratio (RR) Z 0.81 [95% CI, 0.74e0.89]), psychiatric
disorders (IRs, 2.92 and 4.27, RR Z 0.68 [0.48e0.98]) and
neoplasms (IRs, 2.63 and 1.65; RR Z 1.59 [1.00e2.53]).
Most of the frequently-reported adverse events were
reported by similar proportions of patients in the two
treatment groups. The notable exceptions to this were
COPD exacerbation (the most common event reported
overall), which was reported by 641 (32.8%) in the tio-
tropium group and 759 (38.6%) in the placebo group, and
dry mouth, reported by 60 (3.1%) and 27 (1.4%), respec-
tively. After COPD exacerbations, the most common
adverse events across both groups were balanced between
groups, e.g. nasopharyngitis (8.0 and 7.7% respectively),
dyspnoea (7.0 and 7.7%), upper respiratory tract infection
(6.4 and 7.3%) and cough (6.4 and 5.5%) (Table 7).
Fatal events with onset of event and death during the
planned treatment period (up to Day 337) occurred in
52 patients (IR, 2.94) in the tiotropiumgroup and 38 (IR, 2.13)
in the placebo group. The RR for all-causemortality was 1.38
(95% CI, 0.91e2.10; pZ 0.13). The most common causes of
death as adjudicated by the committee were: a) general
disorders and administration site conditions, which include
the preferred terms “death”, “unexplained death” and
“sudden death” (31); b) lower respiratory system disorders
(25); c) cardiac disorders (13) and d) neoplasms (11), classi-
fied either as general neoplasms (excludes lung cancer) or
other respiratory system disorders (lung cancer and pulmo-
nary embolism). Imbalances in event rates favoured tio-
tropium in lower respiratory system disorders and infections
and infestations, and placebo in the other classes (Table 8).
However, the numbers of events were small in some classes,
and CIs for the rate ratio included 1 for all classes.
Apost-hocanalysis ofmajor adversecardiovascularevents
was performed by defining a composite cardiovascular
endpoint that comprised fatal and non-fatal MI and stroke,
Table 5 Patient characteristics at screening and concomitant COPD medication use at randomisation, showing differences
between users and non-users of long-acting beta-agonists (LABAs) at randomisation.
LABA users LABA non-users
Tiotropium 5 mg
Respimat
(n Z 1058)
Placebo
(n Z 1033)
Tiotropium 5 mg
Respimat
(n Z 894)
Placebo
(n Z 932)
Screening visit
Men:women (%) 77.8:22.2 74.2:25.8 78.4:21.6 80.2:19.8
Age (years) 64.9 (9.0) 64.6 (8.8) 64.8 (9.2) 65.0 (9.2)
Current smoker:ex-smoker (%) 33.6:66.4 32.5:67.5 38.3: 61.6 39.6:60.4
Smoking history (pack-years) 46.4 (24.7) 46.0 (26.0) 45.5 (27.7) 43.9 (27.1)
Time since COPD diagnosis (yrs) 8.12 (6.28) 8.41 (6.43) 8.59 (7.76) 7.78 (6.60)
Pre-bronchodilator FEV1 (L) 1.089 (0.383) 1.094 (0.390) 1.105 (0.403) 1.082 (0.401)
Pre-bronchodilator FEV1
(% predicted normal)
39.24 (11.71) 40.03 (11.55) 40.58 (12.36) 39.61 (12.37)
Pre-bronchodilator FVC (L) 2.371 (0.748) 2.366 (0.772) 2.324 (0.723) 2.349 (0.766)
Pre-bronchodilator
FEV1/FVC (%)
46.53 (10.69) 46.92 (10.52) 48.00 (10.91) 46.53 (10.88)
Post-bronchodilator FEV1 (L)
a 1.218 (0.422) 1.219 (0.431) 1.275 (0.462) 1.262 (0.468)
Post-bronchodilator FEV1
(% predicted normal)a
43.85 (12.82) 44.63 (12.78) 46.82 (14.18) 46.16 (14.50)
Reversibility of FEV1 (%) 13.26 (16.23) 12.56 (15.22) 16.60 (17.05) 18.00 (18.38)
Post-bronchodilator FVC (L)a 2.595 (0.787) 2.601 (0.823) 2.595 (0.792) 2.638 (0.849)
Post-bronchodilator
FEV1/FVC (%)
a
47.50 (11.03) 47.49 (10.92) 49.58 (11.43) 48.39 (11.61)
Randomisation visit (baseline)
FEV1 (L) 1.107 (0.396) 1.091 (0.404) 1.111 (0.392) 1.110 (0.392)
FEV1 (% predicted normal) 40.70 (12.29) 39.97 (12.54) 39.94 (11.77) 40.68 (11.69)
FVC (L) 2.343 (0.703) 2.364 (0.756) 2.410 (0.748) 2.402 (0.765)
Proportion taking pulmonary medications (%)b
Any medication 100 100 55.0 54.2
Long-acting b2-agonists 100 100 0 0
Short-acting b2-agonists 38.0 40.0 35.1 34.0
Inhaled corticosteroids 89.7 91.0 16.2 17.5
Oral corticosteroids 2.9 3.1 1.7 2.5
Xanthines 24.7 26.1 21.8 19.5
Mucolytics 11.5 10.4 7.4 7.6
Tiotropiumc 20.2 20.2 4.3 6.2
Short-acting anticholinergics 1.2 1.7 2.1 2.1
Supplementary oxygen 2.3 2.4 1.0 0.8
a Post-bronchodilator values measured 30 min after salbutamol 4  100mg.
b Before or on the randomisation day and for at least 1 day thereafter.
c Proportion of patients taking drug at screening visit (tiotropium withdrawn 28 days before randomisation).
Tiotropium Respimat in COPD patients 1467fatal events in the organ classes cardiac disorders and
vascular disorders, plus the terms sudden death, cardiac
death and sudden cardiac death, all as reported by investi-
gators, for the on-treatment period only. Such events
occurred in 32 tiotropium and 28 placebo patients (IRs, 1.77
and1.58 respectively; RR [tiotropium:placebo], 1.12 [95%CI,
0.67e1.86]). The frequency of stroke was similar in the tio-
tropium and placebo groups (affecting 10 and 11 patients,
respectively).
For all-cause, cardiac and cardiovascular deaths, the
risk was numerically higher in LABA users than in LABA non-
users (Table 9). However, LABA use was not significantly
associated with risk of fatal events when introduced as an
interaction term to a multivariate model that adjusted forfactors such as age, sex and disease severity, i.e. GOLD
stage (p Z 0.724). No clinically relevant differences
between treatment groups were found in vital signs, phys-
ical examination or electrocardiography.
Discussion
In this placebo-controlled study of one-year’s treatment in
3991 patients with moderate-to-severe COPD who were
allowed to continue their usual respiratory medications
(other than inhaled anticholinergics), we have shown that
once daily tiotropium 5 mg delivered via Respimat Soft
Mist Inhaler significantly improved the co-primary
endpoints of trough FEV1 at 48 weeks and the time to first
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1468 E.D. Bateman et al.exacerbation. Improvements were also observed in
secondary endpoints including trough FVC, exacerbation
rate, time to the first exacerbation requiring hospital-
isation, and HRQoL.
The improvements in bronchodilation and exacerbation
rate seen in our study are consistent with those of a pooled
analysis of two one-year trials that compared tiotropium
Respimat 5 and 10 mg with placebo in nearly 2000 COPD
patients with a similar disease profile to our study but
which did not permit concurrent use of LABAs.11 In that
pooled analysis, the difference between tiotropium 5 mg
and placebo for the trough FEV1 endpoint was 127 ml after
one-year’s treatment. The corresponding difference in our
study (102 ml) is of the same order, considering that the
majority of patients were concurrently using LABAs (alone
or in combination with ICS). Of note, the proportions with
at least one exacerbation in our study were 35.3% in the
tiotropium group and 43.1% for placebo, representing
a relative risk reduction (RRR) of 31%, compared with a 22%
reduction in the previous 1-year trials.11 In addition, there
was a 27% reduction in the relative risk of exacerbations
requiring hospitalisation in our study. These results are in
line with those of other reported tiotropium trials,
including the 4-year UPLIFT study with tiotropium 18 mg
delivered via HandiHaler.14
Subgroup analysis according to LABA use at random-
isation was pre-defined in the study protocol, and the
protocol required that drugs being taken at that point be
continued for the rest of the study, which was achieved for
LABAs (99% success rate). Approximately twice as many
patients in the placebo group started LABA therapy after
randomisation as in the tiotropium group. The difference
might have reflected poorer disease control in the placebo
group than in the tiotropium group, which would be
consistent with the efficacy results and could be considered
as a surrogate outcome of efficacy. Improvement in trough
FEV1 and HRQoL throughout the study with tiotropium was
superior to placebo irrespective of LABA co-treatment, but
larger absolute changes from baseline were seen in LABA
non-users than LABA users (for both study treatments). This
probably reflects a greater potential for improvement in
the LABA non-users, who were less heavily treated with
COPD medications before and during the study than LABA
users and had slightly less severe disease. In line with these
results, we also found that fewer LABA non-users than LABA
users (33.4 vs. 44.4%) had at least one exacerbation during
the treatment period. Considering LABA users only, the
superior bronchodilator efficacy of tiotropium relative to
placebo in our study is consistent with the results of short-
and long-term studies that have compared tiotropium and
LABA combinations with LABA only.15e17
More patients discontinued prematurely in the placebo
group than in the tiotropium group, and this effect was
more marked in patients with very severe COPD at baseline.
In both treatment groups, adverse events were the most
common single reason for withdrawal. Safety outcomes
showed few clear differences between the two treatment
groups. Incidence rates for adverse and serious adverse
events were similar, apart from COPD exacerbation and
bronchitis (more common in the placebo group) and dry
mouth (more common in the tiotropium group), for which
the CIs of the rate ratio excluded 1. COPD exacerbation was
Table 7 Number of patients reporting adverse events during the actual treatment period, with incidence rates per 100
patient-years in parentheses (unless otherwise stated). Events are listed by most common organ class and preferred term
(treated set).
Tiotropium 5 mg
Respimat
(n Z 1952)
Placebo
(n Z 1965)
Rate ratio
(tiotropium:placebo),
95% CIa
Mean (SD) exposure to treatment,
days
308.5 (85.9) 299.5 (97.2) e
Any adverse event 1369 (155.6) 1361 (157.4) 0.99 (0.92e1.07)
Any serious adverse event 342 (20.4) 336 (20.6) 0.99 (0.85e1.15)
By organ class (events reported by 5% of patients in either group)
Cardiac disorders 141 (8.03) 131 (7.64) 1.05 (0.83e1.33)
Gastrointestinal disorders 278 (16.9) 238 (14.5) 1.16 (0.98e1.38)
General disorders and
administration site conditions
176 (10.2) 156 (9.26) 1.11 (0.89e1.37)
Infections and infestations 175 (10.2) 201 (12.1) 0.85 (0.69e1.04)
Musculoskeletal and connective
tissue disorders
199 (11.8) 163 (9.7) 1.21 (0.99e1.49)
Nervous system disorders 160 (9.29) 139 (8.18) 1.14 (0.90e1.43)
Lower respiratory system disordersb 902 (70.5) 1013 (87.0) 0.81 (0.74e0.89)
Upper respiratory system disordersb 459 (30.0) 439 (29.1) 1.03 (0.91e1.18)
Preferred term (events reported by 3% of patients in either group)
COPD exacerbation 641 (44.1) 759 (56.8) 0.78 (0.70e0.86)
Nasopharyngitis 157 (9.16) 151 (8.95) 1.02 (0.82e1.28)
Dyspnoea 136 (7.83) 152 (9.02) 0.87 (0.69e1.09)
Upper respiratory tract infection 124 (7.13) 144 (8.51) 0.84 (0.66e1.07)
Cough 124 (7.13) 108 (6.31) 1.13 (0.87e1.46)
Bronchitis 67 (3.79) 95 (5.52) 0.69 (0.50e0.94)
Pneumonia 65 (3.65) 74 (4.25) 0.86 (0.62e1.20)
Productive cough 60 (3.38) 61 (3.52) 0.96 (0.67e1.37)
Dry mouth 60 (3.41) 27 (1.54) 2.21 (1.41e3.49)
CI Z confidence interval; COPD Z chronic obstructive pulmonary disease; SD Z standard deviation.
a Rate ratios calculated from incidence rates.
b The organ class respiratory, thoracic and mediastinal disorders was split into “lower”, “upper” and “other” respiratory disorders.
Tiotropium Respimat in COPD patients 1469the most common adverse event, reported by 36% of
patients. Other adverse events reported by more than 5% of
patients in either group were mainly upper and lower
respiratory events such as nasopharyngitis, dyspnoea,
upper respiratory tract infections and cough. This is similar
to the pattern seen in a pooled analysis of 19 placebo-
controlled trials that compared tiotropium with placebo.18
A numerical imbalance was found in the incidence of
fatal events, which occurred more frequently in the tio-
tropium group. Although inhibition of vagal tone by
systemic anticholinergic agents can result in increased
heart rate, tachycardia has not been observed in this or
other tiotropium trials. A recent meta-analysis of rando-
mised controlled trials in COPD found a significantly higher
rate of cardiovascular death and non-fatal MI or stroke in
patients receiving any inhaled anticholinergics compared
with control,19 but in analyses of tiotropium trials only, the
risk of cardiovascular or all-cause mortality was either
unchanged or reduced compared with placebo.20e22 There
was no indication in our study of a higher risk of stroke in
the tiotropium group, in line with the findings of the
UPLIFT study.14 Fatal events attributed to neoplasms
occurred more often in the tiotropium group than the
placebo group. Considering the diversity of the diagnosesand their timing in relation to the duration of study (fewer
than 100 days for most patients), it is likely that onset pre-
dated study entry. Thus, a causal relationship to tiotropium
treatment is not biologically plausible. In patients concur-
rently using LABAs in our study, there was a numerically
higher risk of all-cause, cardiac and cardiovascular death
with tiotropium, although the association was not signifi-
cant. The use of b2-agonists in patients with asthma and
COPD is itself associated with an increased risk of cardio-
vascular events.23
The mortality results from the current study are incon-
sistent with those of the UPLIFT study, in which the risk of
a fatal event was lower with tiotropium treatment (in the
HandiHaler formulation) than with placebo.14 However, in
the previous 1-year tiotropium Respimat trials, the slight
imbalance in mortality rates favoured placebo although the
difference was not significant.11 In those two trials, the
difference in discontinuation rates between placebo
(31.4%) and tiotropium (18.8% overall) was even more
pronounced than in the current study, and discontinued
patients had more severe lung disease at baseline, partic-
ularly in the placebo group.11
Greater systemic exposure to tiotropium after inhalation
from the Respimat inhaler compared with the
Table 8 Number of fatal adverse eventsa (by organ class) where both onset of event and death occurred during the planned
treatment period (up to Day 337).
Tiotropium 5 mg
Respimat (n Z 1952)
Placebo
(n Z 1965)
Rate ratio
(tiotropium:placebo),
95% CINumber of
events
Incidence
rateb
Number of
events
Incidence
rateb
Patients with any fatal event 52 2.94 38 2.13 1.38 (0.91e2.10)
General disorders and
administration site conditions
19 1.07 12 0.67 1.60 (0.78e3.29)
Lower respiratory system
disorders
9 0.51 16 0.89 0.57 (0.25e1.28)
Cardiac disorders 9 0.51 4 0.22 2.27 (0.70e7.37)
Infections and infestations 3 0.17 5 0.28 0.61 (0.14e2.53)
Other respiratory system
disordersc
5 0.28 2 0.11 2.52 (0.49e13.01)
Neoplasms benign, malignant
and unspecifiedd
4 0.23 2 0.11 2.02 (0.37e11.02)
Other organ classes with 2
events in totale
5 NC 2 NC NC
CI Z confidence interval; NC Z not calculated.
a Adjudicated assignment to organ classes; number of events categorised by class exceeds number of patients in first table row
because some deaths were due to 2 or more events in different classes.
b Per 100 patient-years.
c Comprising lung cancer (tiotropium, 5 events; placebo, 1) and pulmonary embolism (placebo, 1).
d Excluding lung cancer.
e Comprising gastrointestinal disorders (tiotropium 1; placebo, 1); nervous system disorders (tiotropium, 1); psychiatric disorders
(placebo, 1); renal and urinary disorders (tiotropium, 1), reproductive system disorders (tiotropium, 1) and upper respiratory system
disorders (tiotropium, 1).
1470 E.D. Bateman et al.HandiHaler could potentially have influenced outcomes in
the current study. However, a 4-week phase 2 crossover
study that compared daily tiotropium doses of 5 and 10 mg
from Respimat inhaler and 18 mg from the HandiHaler
found that the two inhalers performed similarly in regard to
efficacy and tolerability, and that systemic exposures were
also similar.24 The choice between these two inhalers,
where both are licensed, will depend mainly on the use
characteristics of the device for subgroups of patients with
different needs, and the adequacy of the patient’s inhaler
technique. Patient satisfaction with the Respimat inhaler
has been shown to be high in controlled clinical studies.25,26Table 9 Hazard ratios (HRs) for deaths occurring during the plan
acting beta2-agonists (LABAs) at baseline, from multivariate anal
Chronic Obstructive Lung Disease) stage, body mass index and ca
Patients using LABAs
Number of
patients
analysed
HR (tiotr
placebo)
95% CI
All-cause deathsa Tiotropium, 26;
Placebo, 16
1.40 (0.7
Cardiac deathsb Tiotropium, 10;
Placebo, 2
4.45 (0.9
Cardiovascular deaths Tiotropium, 10;
Placebo, 4
2.25 (0.7
CI Z confidence interval.
a Also adjusted for blood and lymphatic system disorders.
b Also adjusted for renal and urinary disorders (excluding nephropaIn conclusion, once daily tiotropium delivered via
the Respimat inhaler to patients who continued to take
their usual maintenance therapy for COPD produced
improvements in lung function, exacerbation risk and
quality of life after 48 weeks’ treatment. The adverse
event profile was essentially not different from previous
tiotropium trials, except that more fatal events occurred in
the tiotropium Respimat group. Although the clinical
significance of this finding is uncertain given the imprecise
estimate of hazard ratio for all-cause mortality, the
potential influence of trial-related factors and the incon-
sistency with the results reported for tiotropiumned treatment period (up to Day 337) according to use of long-
yses. Ratios adjusted for age, sex, GOLD (Global Initiative for
rdiac disorders.
Patients not using LABAs
opium:
and
Number of
patients
analysed
HR (tiotropium:
placebo) and
95% CI
5e2.62) Tiotropium, 26;
Placebo, 22
1.16 (0.66e2.06)
7e20.38) Tiotropium, 10;
Placebo, 8
1.32 (0.52e3.38)
0e7.18) Tiotropium, 12;
Placebo, 8
1.55 (0.63e3.81)
thies).
Tiotropium Respimat in COPD patients 1471HandiHaler in the larger UPLIFT trial, it will be investi-
gated further in future studies.Acknowledgements
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